Business

AIR001 developer Mast Therapeutics will merge with AeroVanc and Molgradex developer Savara, the companies have announced. Savara's current management team will lead the combined company, which will be called Savara Inc and which will trade under a new stock ticker symbol. After the merger, current Savara stockholders will own ~76% of the combined company, and current … [Read more...] about Mast Therapeutics to merge with Savara

Satsuma Pharmaceuticals, a spin out from Shin Nippon Biomedical Laboratories (SNBL) has closed a $12 million Series A financing co-led by RA Capital Management and TPG Biotech, the company said. Proceeds will be used to fund development of the company's STS101 dihydroergotamine (DHE) intranasal dry powder for the treatment of migraines. In 2013, SNBL announced … [Read more...] about Satsuma Pharmaceuticals spins out from SNBL to develop intranasal dihydroergotamine

Days after its subsidiary Nicovations cancelled supply agreements with Bespak, British American Tobacco says that it and Kind Consumer "have reached a mutually satisfactory agreement on the financial aspects" on "a new approach to commercialize the Voke nicotine inhaler" in which BAT will return the rights to the inhaler to Kind, "allowing Kind to embrace the full … [Read more...] about BAT returns Voke inhaler rights to Kind Consumer

Vectura and Mundipharma have signed an agreement for the development and commercialization of the VR2076 ICS/LABA/LAMA MDI, Vectura has announced. Skyepharma, which was acquired by Vectura earlier this year, had previously announced a development and commercialization deal for the MDI, then known as SKP-2076, in December 2015. Mundipharma and a "US associated … [Read more...] about Vectura and Mundipharma sign development deal for triple therapy MDI

Horizon Pharma has announced that Quinsair levofloxacin inhalation solution is now available in Canada for the treatment of P. aeruginosa lung infections in adult cystic fibrosis patients. Horizon acquired Quinsair when it acquired Raptor Pharmaceutical company in October 2016. Raptor launched Quinsair in Europe in April 2016. Horizon Pharma VP and General Manager, … [Read more...] about Horizon launches Quinsair inhaled levofloxacin in Canada

Sunovion has acquired exclusive US marketing rights to three Novartis DPIs for the treatment of COPD, the company has announced. The company said that it plans to market the Utibron (indacaterol/glycopyrrolate) Neohaler, Seebri (glycopyrrolate) Neohaler, and Arcapta (indacaterol) Neohaler beginning in 2017. Novartis will continue to manufacture the three … [Read more...] about Sunovion gets US rights to Utibron, Seebri, and Arcapta Neohalers

Cephalgia, a startup spun out of the University of Chicago, will receive $250,000 from the university's Innovation Fund for development of intranasal IGF-1 for the treatment of migraine, according to the fund. The company was selected to receive the money after pitching its business plan in a live competition. University of Chicago Associate VP for Entrepreneurship … [Read more...] about Startup Cephalgia gets funding from University of Chicago Innovation Fund for intranasal IGF-1

Intranasal drug developer Impel NeuroPharma has received $21 million in the initial tranche of a Series C financing round, with another $15 million available on completion of development and business milestones, the company said. Investors venBIO, 5AM Ventures and Vivo Capital, contributed equally. Impel NeuroPharma CEO John Hoekman said, “The nasal cavity is a … [Read more...] about Impel NeuroPharma raises $36 million for development of intranasal CNS products